Table 1.
All nonnucleoside reverse-transcriptase inhibitor drug resistance mutations identified by all assays.
| Virologic rebound |
|||
|---|---|---|---|
| Subject | Baseline PBMCa |
Population sequencing |
Allele-specific PCR (% mutant)b |
| 1 | K103N | K103N | … |
| 2 | K103N | K103N | … |
| 3 | G190A | K103N | … |
| 4 | Wild type | K103N | … |
| 5 | Wild type | K103N | … |
| 6 | Wild type | Wild type | K103N (1.19) |
| 7 | Wild type | Wild type | K103N (0.25) |
| 8 | Wild type | Wild type | K103N (0.27) |
| 9 | Wild type | Wild type | K103N (0.51) |
| 10 | Wild type | Wild type | Y181C (0.47) |
| 11 | Wild type | Wild type | K103N (2.11) and Y181C (0.26) |
| 12 | K103N | Wild type | Wild type |
| 13 | K103N | Wild type | Wild type |
| 14 | Y181C | Wild type | Wild type |
NOTE. The oligonucleotide ligation assay was performed on DNA in PBMCs collected at baseline before antiretroviral therapy discontinuation. Virologic rebound was defined as the first detection of an HIV-1 RNA level >5000 copies/mL after antiretroviral therapy discontinuation. Population sequencing was performed at virologic rebound for all patients; allele-specific PCR was performed only if population sequencing did not demonstrate any nonnucleoside reverse-transcriptase inhibitor resistance mutations. PBMC, peripheral blood mononuclear cell.
Detected by oligonucleotide ligation assay.
Allele-specific PCR was not performed on specimens with nonnucleoside reverse-transcriptase inhibitor resistance mutations detected by population sequencing.